lithium carbonate er lithium carbonate tablet

INDICATIONS AND USAGE Lithium Carbonate Extended-Release Tablets are indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. When given to a patient experiencing a manic episode, Lithium Carbonate Extended-Release Tablets may produce a normalization of symptomatology within 1 to 3 weeks.

glenmark pharmaceuticals inc., usa

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] fatigue` `[3] pain` `[4] dyspnoea` `[5] rheumatoid arthritis` `[6] arthralgia` `[7] nausea` `[8] off label use` `[9] diarrhoea` `[10] rash`

6 years ago

ROUND YELLOW G 224

6 years ago

G 224 ROUND YELLOW

HOW SUPPLIED

LITHIUM CARBONATE Extended-Release Tablets USP, 450 mg are supplied as off-white to pale yellow, circular, beveled edged, biconvex uncoated tablets with ‘224’ debossed on one side, ‘G’ and a break line debossed on the other side, in bottles of 30’s, 100’s, and 1000’s. The tablets meet the requirements of USP Dissolution Test 2 in the USP monograph for

LITHIUM CARBONATE Extended-release Tablets USP. Bottles of 30 NDC 68462-224-30 Bottles of 100 NDC 68462-224-01 Bottles of 1000 NDC 68462-224-10

More pills like ROUND G 224

Related Pills

lithium carbonate 450 mg

glenmark pharmaceuticals inc., usa

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site